Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mitchell

Showing results (1-10 of 249) with videos related to

Pageof 25
Sort By:
Nature Biotechnology|October 10, 2009
Firms seek new models to access public equityPeter Mitchell
Nature Biotechnology|July 13, 2010
Microcap public biotechs access new pool of VC fundingPeter Mitchell
Nature Biotechnology|May 12, 2009
Corporate venture funds chase early-stage dealsPeter Mitchell
Nature Biotechnology|August 10, 2016
'Brexit' stuns UK biotech into waiting game, but not all signals are redPeter Mitchell
Nature Medicine|February 4, 2003
Europe dithers over stem cell patentsPeter Mitchell
Nature Biotechnology|April 3, 2004
Erbitux diagnostic latest adjunct to cancer therapyPeter Mitchell
Nature Biotechnology|December 4, 2003
Europe responds to UK's GM field trialsPeter Mitchell
Nature Biotechnology|May 4, 2004
Bioinformatics attracts big gunsPeter Mitchell
Nature Biotechnology|June 4, 2004
Sanofi takeover jeopardizes Aventis biotech dealsPeter Mitchell
Nature Biotechnology|November 9, 2007
Antibodies' long revenue stream spurs pharma acquisitionsPeter Mitchell
Pageof 25

Showing results (1-10 of 249) with videos related to

Sort By:
Pageof 25
Nature Biotechnology|October 10, 2009
Firms seek new models to access public equityPeter Mitchell
Nature Biotechnology|July 13, 2010
Microcap public biotechs access new pool of VC fundingPeter Mitchell
Nature Biotechnology|May 12, 2009
Corporate venture funds chase early-stage dealsPeter Mitchell
Nature Biotechnology|August 10, 2016
'Brexit' stuns UK biotech into waiting game, but not all signals are redPeter Mitchell
Nature Medicine|February 4, 2003
Europe dithers over stem cell patentsPeter Mitchell
Nature Biotechnology|April 3, 2004
Erbitux diagnostic latest adjunct to cancer therapyPeter Mitchell
Nature Biotechnology|December 4, 2003
Europe responds to UK's GM field trialsPeter Mitchell
Nature Biotechnology|May 4, 2004
Bioinformatics attracts big gunsPeter Mitchell
Nature Biotechnology|June 4, 2004
Sanofi takeover jeopardizes Aventis biotech dealsPeter Mitchell
Nature Biotechnology|November 9, 2007
Antibodies' long revenue stream spurs pharma acquisitionsPeter Mitchell
Pageof 25